Next Phase Newsletter

A private equity firm founded in the USA invests in companies with high growth potential. The firm also considers in-licensing of technologies and strategic acquisitions. For equity investments, the firm prefers that companies are located in the Eastern US and Midwest, but for acquisitions and in-licensing, the firm will consider companies located around the globe. The firm also has an early-stage focused fund through which the firm makes angel investments into high potential, early-stage companies. With this fund, the firm typically invests up to $250K in preferred equity.

The firm primarily focuses on the following sectors: Diagnostics (including digital), Pharma Services/Outsourcing, Digital Health, and Medical Devices. The firm has a strong preference for companies working with platform technologies. For equity investments, the firm looks for companies that have reached commercialization. With regards to their early-stage fund, the firm primarily seeks companies in healthcare services and SaaS outsourcing businesses.

The firm is looking for experienced management teams with domain expertise and leadership skills that are capable of taking the company to the next value inflection point or additional capital raise. The firm is interested in company that are profitable or near breakeven and have demonstrated substantial opportunity for growth.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An investment holding company based in China specializes in equity investment, debt financing, and equity investment services. With capital commitment from both public and private investors, the firm currently has total assets under management of over RMB 29 billion (USD $4.5 billion). Typical equity allocations range from US$2-6 million in an early-stage company, while the firm can participate from pre-series A to pre-IPO financing rounds. The firm is currently seeking opportunities from China, the US, and the EU.

The firm currently focuses on pharmaceuticals, medical devices, and IVD tools in late clinical development or early preclinical stage with high entry battier and market potential.

The firm is looking for experienced management teams. The firm typically syndicates with other investors and takes 10%-20% minority stake in a financing round. Board representation is often required. The firm prefers China-based companies, Chinese-owned foreign businesses, or products with a China-angle; however, this is not a requirement. The firm can provide its expertise to help with registration, distribution, M&A, and formation of the joint venture and strategic partnerships in the country.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A sector-exclusive life sciences venture and growth equity fund focused on Asia, particularly China, is currently investing from its latest fund closed in 2019. The firm is stage agnostic, investing as early as seed, growth, and up to pre-IPO opportunities. The firm has a team of investment professionals all with healthcare background. Investment size is USD $5-25 million per company. The firm prefers to lead or co-lead a financing round, and while the firm focuses on China they also consider opportunities from USA.

In life sciences, the firm is focused on therapeutics with an emphasis on oncology, metabolic disorders, cell therapy, and biologics, etc. The firm is also interested in medical devices and diagnostics. The firm is opportunistic to the indication and the phase of development and will consider products in pre-clinical up to NDA.

The firm is seeking experienced management teams that are going rapidly and emerging as market leaders.  The firm is seeking companies developing technologies that are truly based on high quality science, but also aligned with the potential of attractive financial return. Because the firm focuses its activities in China, the firm will prefer companies outside of China to have a strong China angle. The firm typically requires a board seat or observation rights post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based private investment firm is focused on healthcare companies. The firm makes seed, venture, and growth stage investments. The firm typically provides seed and Series A equity financing in the range of $100K to $1M per portfolio company. The firm generally acts as the lead investor and is open to investing in syndicates. The firm is open to opportunities across North America and is actively seeking new investment opportunities.

The firm is currently seeking to invest in medical devices, diagnostics, digital health, and software. The firm is also interested in reformulated and repurposed drugs that have mitigated risk. For medical devices, the firm is opportunistic in terms of subsectors. Ideally, the product has a prototype and 510(k) regulatory pathway. The firm is open to investing in any indication, including orphan diseases; the dental field is of interest.

The firm seeks a strong and experienced management team. The firm may take a board seat where appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture arm of a global company seeks to make strategic investments into early-stage companies that are aligned with the company’s R&D focus. For equity investments, the firm will lead, co-lead, or participate in syndicated financings. With deep connections into the firm’s global research and development centers, the firm is ideally placed to nurture innovative pharmaceutical companies and to connect these into the parent company.

The firm’s core focus is on therapeutics. Currently, the firm is most interested in oncology, gastrointestinal diseases, neuroscience and rare disease. The firm is also interested in breakthrough platform technologies that improve peptide, antibody, cell, and gene based therapies. The firm does not invest in medical devices or diagnostics.

The firm’s primary focus is on start-up/seed rounds, through mid-stage financings – pre-clinical through Phase II. The firm respects the autonomy of the institutions it invests in and seeks standard institutional venture investment terms without special rights or options.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in USA and Canada is exclusively focused on supporting entrepreneurs commercializing advanced materials and advanced material process innovations within four verticals: energy, electronics, health, and sustainability. The firm typically makes initial investments in the $1M-$4M range and up to $8M over the life of the investment (more or less may be initially invested depending on the deal). The firm prefers to lead deals but will also participate in a syndicate as a co-investor. The firm has strategic LP relationships in Asia, Europe, the Middle East, and North America and invests globally.

Within healthcare, the firm is interested in medical devices and diagnostics whose underlying technology is enabled by advanced materials or advanced material process innovations. The firm has a particular interest in 3D bioprinting, diagnostics and genomics/proteomics R&D applications. The firm does not make investments in pharmaceuticals/therapeutics. Past investments have included a manufacturer of semiconductor radiation detectors enabling a new generation of detection and imaging equipment, a company developing a disruptive 3D bioprinting platform, and a company developing functional surfaces with anti-microbial and anti-fouling properties.

The firm prefers to work with experienced management teams, but is open to working with less experienced entrepreneurs or incomplete management teams given the firm can add value through corporate strategy and operational experience to help accelerate development. The firm prefers to invest in revenue-generating companies but is open to evaluating pre-revenue companies as well. The firm typically seeks a board seat along with investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A healthcare-focused venture investment fund with a team who are all trained in biomedical fields, with healthcare industry experience and years of successful investment or entrepreneurship experience in China, has past investment portfolio companies cover areas such as drug, device, diagnostics, healthcare IT and medical services. These investments were over $10MM and were made in venture rounds from Series A-C. The firm currently manages both RMB and US Dollar funds, investing in early and growth-stage companies in China and overseas. The firm believes in the huge industry growth and significant investment opportunities in China healthcare space for the next 10 to 20 years.

The firm has invested in therapeutics in a wide range of indications, including cancer, infectious diseases and autoimmune disorders. These investments covered a wide range of modalities including small molecules, antibodies and gene therapies. The firm additionally invested in medical device and imaging technologies, such as ultrasound and cardiovascular devices. Therapeutic investments were made during pre-clinical trials, while device investments were made pre-market. The firm invested in bioinformatics, research tools and animal medicine as well. The firm has invested in companies in the US, China and Western Europe.

The firm has no specific management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.